MedTrace Logo

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

NCT00394745 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.

Conditions

Interventions

DRUG

Valsartan

Sponsors & Collaborators

Principal Investigators

  • Novartis + 41 61 324 1111 Basel · Novartis Basel+ 41 61 324 1111

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394745 on ClinicalTrials.gov